Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma

Online First - FDA Updates

On April 25, 2016, the FDA approved cabozantinib (Cabometyx; Exelixis) for the treatment of patients with advanced renal-cell carcinoma (RCC) who had received anti-angiogenic therapy. The FDA granted this approval under its fast track and priority review procedures.
           

The approval was based on 1 randomized clinical trial of patients with advanced RCC who had previously received anti-angiogenic therapy and were randomized to oral cabozantinib 60 mg daily (N = 330) or to everolimus 10 mg orally once daily (N = 328). The primary end point was progression-free survival (PFS) in the first 375 randomized patients.

The median PFS in this group was 7.4 months with cabozantinib and 3.8 months with everolimus (P <.001). The median overall survival in the full study population was 21.4 and 16.5 months, respectively. The response rate was 17% versus 3%, respectively. 

The safety of cabozantinib was evaluated in 331 patients. The most common adverse reactions included diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, hypertension, vomiting, weight loss, and constipation. In addition, 60% of patients receiving cabozantinib had ≥1dose reduction. Serious adverse events were reported in 40% of patients; these included abdominal pain, pleural effusion, diarrhea, and nausea. The recommended dose and schedule for cabozantinib is 60 mg orally daily. 

Cabozantinib received a breakthrough therapy designation from the FDA in August 2015.

Related Items
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in FDA Updates
FDA Approved Truseltiq for Metastatic Cholangiocarcinoma with the FGFR2 Biomarker
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in FDA Updates
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Web Exclusives published on August 10, 2021 in FDA Updates
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Web Exclusives published on August 10, 2021 in FDA Updates
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial
Web Exclusives published on August 3, 2021 in FDA Updates
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.